These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 32955967)
1. Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement. Mandell KJ; Clark D; Chu DS; Foster CS; Sheppard J; Brady TC J Ocul Pharmacol Ther; 2020 Dec; 36(10):732-739. PubMed ID: 32955967 [No Abstract] [Full Text] [Related]
2. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease. Clark D; Sheppard J; Brady TC J Ocul Pharmacol Ther; 2021 May; 37(4):193-199. PubMed ID: 33450164 [No Abstract] [Full Text] [Related]
3. Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. Foster CS; Davanzo R; Flynn TE; McLeod K; Vogel R; Crockett RS J Ocul Pharmacol Ther; 2010 Oct; 26(5):475-83. PubMed ID: 20809807 [TBL] [Abstract][Full Text] [Related]
4. Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease. Clark D; Tauber J; Sheppard J; Brady TC Am J Ophthalmol; 2021 Jun; 226():22-31. PubMed ID: 33529588 [TBL] [Abstract][Full Text] [Related]
5. Iontophoretic Dexamethasone Phosphate Compared to Topical Prednisolone Acetate 1% for Noninfectious Anterior Segment Uveitis. Sheppard J; Garg S; Lievens C; Brandano L; Wirostko B; Korenfeld M; Raizman M; Foster CS Am J Ophthalmol; 2020 Mar; 211():76-86. PubMed ID: 31726034 [TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and ocular surface toxicity of topical preservative-free methylprednisolone and preserved prednisolone in the treatment of acute anterior uveitis. Hedayatfar A; Hashemi H; Asgari S; Chee SP Cornea; 2014 Apr; 33(4):366-72. PubMed ID: 24351572 [TBL] [Abstract][Full Text] [Related]
7. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Sheppard JD; Toyos MM; Kempen JH; Kaur P; Foster CS Invest Ophthalmol Vis Sci; 2014 May; 55(5):2993-3002. PubMed ID: 24677110 [TBL] [Abstract][Full Text] [Related]
8. Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. Wilson ME; O'Halloran H; VanderVeen D; Roarty J; Plager DA; Markwardt K; Gedif K; Lambert SR Eye (Lond); 2016 Sep; 30(9):1187-94. PubMed ID: 27367745 [TBL] [Abstract][Full Text] [Related]
10. A single intraoperative sub-Tenon's capsule triamcinolone acetonide injection for the treatment of post-cataract surgery inflammation. Paganelli F; Cardillo JA; Melo LA; Oliveira AG; Skaf M; Costa RA; Ophthalmology; 2004 Nov; 111(11):2102-8. PubMed ID: 15522378 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis--a randomized triple masked study. Biswas J; Ganeshbabu TM; Raghavendran SR; Raizada S; Mondkar SV; Madhavan HN Int Ophthalmol; 2004 May; 25(3):147-53. PubMed ID: 15847313 [TBL] [Abstract][Full Text] [Related]
12. Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial. Clark D; Cavanagh B; Shields AL; Karpecki P; Sheppard J; Brady TC Am J Ophthalmol; 2021 Oct; 230():60-67. PubMed ID: 33945820 [TBL] [Abstract][Full Text] [Related]
13. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Foster CS; Alter G; DeBarge LR; Raizman MB; Crabb JL; Santos CI; Feiler LS; Friedlaender MH Am J Ophthalmol; 1996 Aug; 122(2):171-82. PubMed ID: 8694085 [TBL] [Abstract][Full Text] [Related]
16. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Thorne JE; Woreta FA; Dunn JP; Jabs DA Ophthalmology; 2010 Jul; 117(7):1436-41. PubMed ID: 20363502 [TBL] [Abstract][Full Text] [Related]
17. Risk of Cataract Development among Children with Juvenile Idiopathic Arthritis-Related Uveitis Treated with Topical Corticosteroids. Thorne JE; Woreta FA; Dunn JP; Jabs DA Ophthalmology; 2020 Apr; 127(4S):S21-S26. PubMed ID: 32200821 [TBL] [Abstract][Full Text] [Related]
18. A multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgery. Donnenfeld ED; Holland EJ; Solomon KD; Fiore J; Gobbo A; Prince J; Sandoval HP; Shull ER; Perry HD Am J Ophthalmol; 2011 Oct; 152(4):609-617.e1. PubMed ID: 21704965 [TBL] [Abstract][Full Text] [Related]
19. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. Lane SS; Holland EJ J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255 [TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of topical prednisolone acetate 1% versus fluorometholone 0.1% in the first year after descemet membrane endothelial keratoplasty. Price MO; Price FW; Kruse FE; Bachmann BO; Tourtas T Cornea; 2014 Sep; 33(9):880-6. PubMed ID: 25062336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]